Business Numinus gets new biosecurity licence to expand psilocybin research CEO Payton Nyquvest says the authorization moves his firm closer to developing medicines at scale to support psychedelic-assisted therapy Nick LabaMarch 14, 2022
Business Numinus submits novel psilocybe formulation for clinical trial If approved, it will mark the firm's first independent clinical trial with a proprietary extract Nick LabaJanuary 14, 2022
Business Numinus develops in-house tests to detect compounds in psychedelic mushrooms The methods will be available as part of third-party client services Nick LabaNovember 29, 2021